Filing Analysis
Journey Medical Corp issued an 8-K to announce its financial results for the three months ended June 30, 2026. The filing serves as a vehicle to furnish a corporate update and press release via Exhibit 99.1.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Three months ended June 30, 2026
- The filing includes a corporate update and financial results via press release (Exhibit 99.1)
- Company is an emerging growth company
Journey Medical Corporation held its 2026 Annual Meeting of stockholders on June 24, 2026. The meeting resulted in the successful election of six directors and the ratification of KPMG LLP as the company's independent auditor for the fiscal year ending December 31, 2026.
🚩 Red Flags
- High concentration of voting power: Class A Common Stock holds 3.91 votes per share, which can be used to control company decisions despite lower equity ownership.
📋 Key Facts
- Annual Meeting held on June 24, 2026, via virtual platform.
- Quorum was achieved with 81% of total voting shares represented (16,145,526 Common and 6,000,000 Class A Common).
- Six directors were elected to hold office until the 2027 annual meeting: Lindsay A. Rosenwald, Claude Maraoui, Neil Herskowitz, Justin Smith, Miranda Toledano, and Michael Pearce.
- KPMG LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Class A Common Stock carries a significant voting weight of 3.91 votes per share.
Journey Medical Corporation announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- The report covers the three-month period ended March 31, 2026.
- The filing was made on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The press release (Exhibit 99.1) includes both financial results and a general corporate update.
Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, its treatment for inflammatory lesions of rosacea in adults. The announcement was made via a press release on April 21, 2026, and filed under Item 8.01.
📋 Key Facts
- The product involved is Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules).
- The expansion pertains to pharmacy benefit coverage, which typically improves patient access and potential sales volume.
- The announcement was dated April 21, 2026.
- The filing includes a press release as Exhibit 99.1.
Journey Medical Corporation announced its financial results for the full year ended December 31, 2025, and provided a corporate update via a press release on March 25, 2026.
📋 Key Facts
- The company reported financial results for the fiscal year ended December 31, 2025.
- The announcement was made on March 25, 2026.
- The press release was furnished under Item 2.02 and included as Exhibit 99.1.
- Journey Medical is classified as an emerging growth company.
Journey Medical Corp issued an 8-K to announce its financial results for the three months ended September 30, 2025. The filing serves as a vehicle to furnish a corporate update and press release regarding recent operations.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Three months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) providing a corporate update and financial results.
- Company is classified as an 'emerging growth company'.
Journey Medical Corporation entered into a Third Amendment to its $25.0 million term loan facility with SWK Funding LLC on September 25, 2025. The amendment extends the maturity date and modifies revenue-based repayment triggers.
🚩 Red Flags
- Modification of repayment terms suggests a need for more flexible cash flow management.
- The company has already drawn the full $25.0 million of its credit facility, indicating no further immediate liquidity from this specific source.
📋 Key Facts
- The Third Amendment extends the Term Loan maturity date from December 27, 2027, to June 27, 2028.
- Total principal amount drawn is $25.0 million.
- Repayment terms: Starting February 2026, quarterly repayments of 7.5% of the principal are required.
- Revenue-based deferral: If TTM revenue > $60.0M as of Dec 31, 2025, principal repayment is deferred until February 2027 and the rate increases to 10.0% quarterly (previously 15.0%).
- The amendment lowers the revenue threshold for deferral from $70.0 million to $60.0 million.
Journey Medical Corp. entered into a new At-The-Market (ATM) sales agreement to offer up to 3,750,000 shares of common stock through B. Riley Securities and Lake Street Capital Markets. Simultaneously, the company terminated its previous ATM agreement with B. Riley which had previously facilitated the sale of over 4.1 million shares.
🚩 Red Flags
- Continuous use of ATM offerings suggests a recurring need for equity financing to support operations (dilutive).
📋 Key Facts
- New Sales Agreement dated August 28, 2025, with B. Riley Securities and Lake Street Capital Markets.
- The new offering allows for the sale of up to 3,750,000 shares of common stock.
- Agents will receive a 3.0% commission on gross proceeds from sales.
- Termination of the original Sales Agreement (dated Dec 30, 2022) effective August 28, 2025.
- The company has previously sold 4,121,318 shares under the terminated agreement.
Journey Medical Corp issued an 8-K to announce its financial results for the three months ended June 30, 2025. The filing serves as a vehicle to furnish a corporate update and press release via Exhibit 99.1.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Three months ended June 30, 2025
- The filing includes a corporate update and financial results via press release (Exhibit 99.1)
- Company is classified as an emerging growth company
Journey Medical Corporation announced an expansion in pharmacy benefit coverage for its recently launched rosacea treatment, Emrosi™. This development is intended to increase patient access and market penetration for the product.
📋 Key Facts
- Product: Emrosi™ (Minocycline Hydrochloride Capsules in 10mg IR, 30mg ER, and 40mg MR formulations).
- Announcement Date: July 14, 2025.
- Event: Expansion of pharmacy benefit coverage for the treatment of inflammatory lesions of rosacea in adults.
Journey Medical Corporation held its 2025 Annual Meeting of Stockholders on June 24, 2025. Shareholders approved the election of six directors, the ratification of KPMG LLP as independent auditors, and an amendment to the charter to provide for officer exculpation.
🚩 Red Flags
- Approval of officer exculpation in the Fourth Amended and Restated Charter (reduces personal liability for officers/directors).
📋 Key Facts
- Annual Meeting held on June 24, 2025 via virtual platform.
- Quorum reached with 85.04% of total voting shares represented (19,663,140 Common and 6,000,000 Class A).
- Six directors were elected to hold office until the 2026 annual meeting: Lindsay A. Rosenwald, Claude Maraoui, Neil Herskowitz, Justin Smith, Miranda Toledano, and Michael Pearce.
- KPMG LLP was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- The Fourth Amended and Restated Charter was approved, which includes provisions for officer exculpation.
Journey Medical Corporation announced its inclusion in the Russell 2000® and Russell 3000® Indices, effective after market close on June 27, 2025. This is a positive milestone typically associated with increased liquidity and institutional index tracking.
📋 Key Facts
- Company will join the small-cap Russell 2000® Index
- Company will join the broad-market Russell 3000® Index
- Effective date: After the close of U.S. equity markets on June 27, 2025
Journey Medical Corporation filed an 8-K to announce its quarterly financial results for the three months ended March 31, 2025. The filing serves as a vehicle to furnish a press release containing corporate updates and operational performance data.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes Exhibit 99.1 (Press Release) containing financial results and corporate updates.
- Company is classified as an 'emerging growth company'.
Journey Medical Corporation announced the appointment of Ramsey Alloush as Chief Operating Officer, effective April 1, 2025. Mr. Alloush will retain his existing roles as General Counsel and Corporate Secretary.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Ramsey Alloush appointed as Chief Operating Officer (COO) on April 1, 2025.
- Mr. Alloush will continue to serve as the Company's General Counsel and Corporate Secretary.
- New compensation includes an annualized base salary of $392,945.
- Eligibility for a cash bonus target of 50% of base salary based on performance.
- Participation in the 2015 Stock Plan and other equity award eligibility.
Journey Medical Corporation issued an 8-K to provide a corporate update and announce its full-year financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 26, 2025
- Reporting period: Full year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing corporate updates and financial results.
- Company is an emerging growth company.
Journey Medical Corporation announced the commercial launch of Emrosi™, a line of Minocycline Hydrochloride capsules for treating inflammatory rosacea lesions in adults. The company confirmed that the first prescriptions have already been filled.
📋 Key Facts
- Product Name: Emrosi™ (Minocycline Hydrochloride).
- Dosage forms include 40 mg Modified-Release, 10 mg immediate release, and 30 mg extended release capsules.
- Indication: Treatment of inflammatory lesions of rosacea in adults.
- Status: Commercial launch completed; first prescriptions have been filled as of March 24, 2025.
Journey Medical Corporation provided preliminary financial results for the fiscal year ended December 31, 2024, and reaffirmed its full-year guidance. The company also announced a conference call to discuss the commercial launch plan for its recently approved product, Emrosi™.
🚩 Red Flags
- Forward-looking statements include general risk disclosures regarding 'substantial doubt about our ability to continue as a going concern' in the boilerplate section.
📋 Key Facts
- Expected cash and cash equivalents as of Dec 31, 2024: $20.3 million.
- Reaffirmed FY 2024 Net Product Revenue guidance: $55 - $60 million.
- Reaffirmed FY 2024 SG&A expense guidance: $39 - $42 million.
- Reaffirmed FY 2024 R&D expense guidance: $8 - $10 million.
- Scheduled a conference call to update investors on the commercial launch of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg).
Journey Medical Corp issued an 8-K to announce its quarterly financial results for the three months ended September 30, 2024. The filing serves as a vehicle to furnish a press release containing corporate updates and operational performance data.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Three months ended September 30, 2024
- The filing includes Exhibit 99.1 (Press Release) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Journey Medical announced the FDA approval of Emrosi (formerly DFD-29) for treating rosacea lesions. The approval triggers a $15 million milestone payment to Dr. Reddy’s Laboratories and necessitates a mandatory $5 million draw on their existing credit facility.
🚩 Red Flags
- Significant cash outflow: $15 million milestone payment due immediately following approval.
- Increased net loss for the nine-month period ended Sept 30, 2024 ($16.2M vs -$1.7M in prior year) primarily due to lack of comparable licensing income from Maruho.
📋 Key Facts
- FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) on November 4, 2024.
- Approval triggers a $15.0 million milestone payment to Dr. Reddy’s Laboratories (DRL), due within 30 days.
- Company must draw the remaining $5.0 million from its SWK Funding LLC credit facility in Q4 2024 to fund part of the DRL payment.
- Preliminary Q3 2024 net product revenue was $14.6 million, down from $15.3 million in Q3 2023.
- Q3 2024 gross margin improved to 63.9% from 59% in Q3 2023.
- Company expects Emrosi supply to be available in late Q1 or early Q2 2025.
- Recovery of $4.4 million related to a 2021 cybersecurity fraud loss is expected in Q4 2024.
Journey Medical Corporation issued an 8-K to provide a corporate update and announce financial results for the second quarter ended June 30, 2024. The filing serves as a vehicle to furnish the press release containing these results.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Three months ended June 30, 2024
- The company is an emerging growth company
- Financial results were released via press release (Exhibit 99.1)
Journey Medical Corp amended its credit agreement with SWK Funding LLC to increase the term loan facility from $20 million to $25 million, contingent upon FDA approval of their DFD-29 product candidate by June 30, 2025. The company also appointed Michael C. Pearce to its Board of Directors and adopted a Deferred Compensation Plan.
🚩 Red Flags
- Contingent financing: The final $5M of the credit facility is tied to a binary regulatory event (FDA approval).
- High interest rate environment: SOFR + 7.75% represents significant cost of capital.
- Prepayment penalties and exit fees increase the cost of refinancing or early debt settlement.
📋 Key Facts
- Increased term loan facility from $20 million up to $25 million.
- Additional $5 million draw is contingent on FDA approval of DFD-29 by June 30, 2025 (the 'DFD-29 Advance Condition').
- Current drawn amount: $20 million ($15M term loan + $5M June 2024 advance).
- Interest rate: 3-month term SOFR plus 7.75% (with a 5% SOFR floor).
- Repayment terms: Quarterly principal repayment of 7.5% starting February 2026, unless revenue >$70M TTM as of Dec 31, 2025, in which case repayment starts Feb 2027 at 15% quarterly.
- Prepayment penalty includes a 2% premium if prepaid within the first year and 1% thereafter; an exit fee of 5% is due upon full repayment.
- Appointed Michael C. Pearce to the Board of Directors; he will receive 30,000 RSUs vesting over three years plus annual compensation.
- Adopted a Deferred Compensation Plan for non-employee directors and select executives.
Journey Medical Corporation announced the results of its 2024 Annual Meeting of Stockholders held on June 25, 2024. Shareholders approved the election of five directors, the ratification of KPMG LLP as independent auditors, and an amendment to the 2015 Stock Incentive Plan.
📋 Key Facts
- Stockholders approved increasing the number of shares authorized under the 2015 Stock Incentive Plan by 3,000,000 shares (totaling 10,642,857).
- The expiration date of the 2015 Plan was extended by 10 years to May 27, 2035.
- Five directors were elected: Lindsay A. Rosenwald, M.D., Claude Maraoui, Neil Herskowitz, Justin Smith, and Miranda Toledano.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- A quorum was established with 61.79% of outstanding shares represented at the meeting.
Journey Medical Corp issued an 8-K to furnish a press release containing a corporate update and financial results for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes a corporate update and financial results via Exhibit 99.1
- Company is an emerging growth company
Journey Medical Corporation has appointed Joseph Benesch as its permanent Chief Financial Officer, transitioning him from his interim role held since January 2023.
📋 Key Facts
- Joseph Benesch appointed as permanent CFO effective April 26, 2024.
- Mr. Benesch has served as the Company's interim CFO since January 27, 2023.
- No changes were made to Mr. Benesch's compensation package as a result of this appointment.
- The Board confirmed no family relationships or undisclosed material interests exist regarding the appointment.
Journey Medical Corp issued an 8-K to announce the release of its full-year financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the corporate update and earnings press release.
📋 Key Facts
- Report date: March 21, 2024
- Reporting period: Full year ended December 31, 2023
- The company issued a press release (Exhibit 99.1) containing corporate updates and financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Journey Medical Corp entered into a $20 million term loan facility with SWK Funding LLC on December 27, 2023. The company immediately drew $15 million of the available credit to bolster liquidity.
🚩 Red Flags
- High interest rate environment (SOFR + 7.75% with a 5% floor).
- Asset-backed security: The loan is secured by 'all or substantially all' of the company's assets.
- Prepayment penalties apply if repaid within the first two years.
📋 Key Facts
- Entered into a Credit Agreement with SWK Funding LLC and other lenders on December 27, 2023.
- Total facility amount: up to $20 million; $15 million drawn at closing.
- Maturity date set for December 27, 2027.
- Interest rate: three-month term SOFR (floor of 5%) plus 7.75%.
- Repayment terms: Quarterly principal repayment starting February 2026 (7.5% of principal), unless revenue exceeds $70M TTM by end of 2025, which would defer payments to February 2027 at a 15% rate.
- Secured by all or substantially all of the Company's and its subsidiaries' assets.
- Origination fee paid: $200,000.